WO2009016466A2 - A process for the preparation of naratriptan hydrochloride - Google Patents
A process for the preparation of naratriptan hydrochloride Download PDFInfo
- Publication number
- WO2009016466A2 WO2009016466A2 PCT/IB2008/001971 IB2008001971W WO2009016466A2 WO 2009016466 A2 WO2009016466 A2 WO 2009016466A2 IB 2008001971 W IB2008001971 W IB 2008001971W WO 2009016466 A2 WO2009016466 A2 WO 2009016466A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- naratriptan
- ethyl
- process according
- solvent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to an improved process for the preparation of Naratriptan and its pharmaceutically acceptable salt, an antimigraine drug.
- Naratriptan hydrochloride is a selective 5-hydroxytryptamine-l receptor subtype agonist. It is chemically designated as N-methyl-3-(l-methyl-4-piperidinyl)- lH-indole-5-ethanesulfonamide monohydrochloride and represented by the following formula I
- 2-(lH-indol-5-yl)-N-methylethane sulfonamide of formula III is one of the key intermediates in the synthesis of Naratriptan hydrochloride, which is obtained by decarboxylation of 5- ⁇ 2-[methylamino)sulfonyl]ethyl ⁇ -lH-indole-2-carboxylic acid of formula II.
- N-methyl-3-(l-methyl-4-piperidinyl)-lH-indole-5-ethanesulfonamide and its physiologically acceptable salts are reported in British patent GB2208646 for the treatment of human suffering from migraine, cluster headache and chronic paroxysmal hemicrania.
- the present inventors found that using water along with alcohol for the condensation of l-methylpiperidine-4-one with 2-(lH-indol-5yl)-N- methylethanesulfonamide not only reduces the reaction time but it reduces the formation of impurity significantly.
- the inventors also surprisingly found that purification of the Naratriptan base by using an organic solvent or a mixture of it with water, gives a highly pure product.
- the present invention has following advantages.
- the process involves simple and cheap reagents like ethyl pyruvate, HBr in acetic acid, sulfolane etc.,
- the main objective of the present invention is to provide a novel process for the preparation of Naratriptan Hydrochloride.
- Another objective of the present invention is to provide a process which results in better yield and purity.
- Yet another objective of the process is to provide a process, which is more economical and commercially viable in industrial scale.
- the present invention provides a process for the preparation of Naratriptan and its pharmaceutical acceptable salts comprising the steps of:
- the condensation of 2-(4- hydrazinophenyl)-N-methylethanesulfonamide of Formula V with ethyl 2- oxopropanate of formula VI to get Ethyl (2Z)-2-[(4- ⁇ methylamino) sulfonyl]ethyl ⁇ phenyl) hydrazono] propanate of formula VII is carried out in an alcohol selected from the group consisting of methanol, ethanol, propanol and isopropanol, preferably methanol.
- the cyclisation is carried out using HBr in acetic acid.
- saponification is carried out in aqueous alkali solution, where alkali solution is selected from NaOH, KOH and the like,
- the decarboxylation of 5- ⁇ 2- [(methylamino) sulfonyl] ethyl ⁇ -lH-indole-2-carboxylic acid is carried out using catalytic amount of copper or copper salts and sulfolane as a solvent.
- the condensation of 2-(lH-indol-5- yl)-N-methylethanesulfonamide with l-methylpiperidin-4-one is carried out in presence of alkali using Organic or aqueous organic solution, wherein, organic solvent is selected from -methanol, ethanol, n-propanol, isopropanol and the like, preferably methanol.
- the hydrogenation of N- methyl-2-[3-(l-methyl-l,2,3,6-tetrahydr ⁇ pyridin-4-yl)-lH-indol-5-yl]ethane sulfonamide is carried out in presence of Pd/C using organic solvent with acetic acid to get Naratriptan free base.
- organic solvent is methanol.
- the conversion of Naratriptan free base to hydrochloride salt is carried out by dissolving Naratriptan free base in an organic solvent and converting to hydrochloride using alcoholic HCl.
- the organic solvent is selected from methanol, ethanol, n-propanol, isopropanol, esters such as ethyl acetate and the like and alcoholic HCl is MeOH/HCl, EtOH/HCl or IPA/HC1.
- reaction is performed at a temperature in the range of -10 0 C to reflux temperature preferably 20 to 200 0 C.
- Ethyl (2Z)-2-[(4- ⁇ 2-[(methylamino) sulfonyl] ethyl ⁇ phenyl) hydrazono] propanoate was taken in glacial aceticacid. 33% HBr in acetic acid was added drop wise at 20-30 0 C and stirred for 2 hours then cooled. Water was added drop wise to separate the solid, filtered and washed with water.
- Ethyl 5- ⁇ 2-[(methylamino) sulfonyl] ethyl ⁇ -IH-indole-2-carboxylate was taken in sodium hydroxide in water.
- the reaction mass was heated for 1 hours at 50-60 0 C, stirred and cooled.
- the pH was adjusted to ⁇ 2-3 by using 1 : 1 hydrochloric acid.
- the solid was separated out, filtered and washed with water. The solid was dried at 60-70 0 C
- N-methyl-2-[3-(l-methyl-l,2,3,6 tetrahydopyridin-4-yl)-lH-indol-5yl]-ethane sulfonamide (5 g) was dissolved in methanol and acetic acid in 1 lit autoclave. To this solution, 5% wet Pd/C was added. Hydrogen was flushed to the reaction mass at room temperature. The pressure was maintained at 10 kg. After completion of the reaction, the reaction mass was filtered through Hyflow and concentrated. A solution of sodium carbonate and ethyl acetate was added to the reaction mass and stirred. The aqueous layer was extracted with ethylacetate and combined organic layer was charcolised with 10% carbon. The filtrate was distilled up and cooled to room temperature and stirred for another 30 minutes. The reaction mass was filtered and washed with ethylacetate. The solid obtained was dried to obtain 3.5 gm of the title product.
- the Naratriptan base was dissolved in acetonitrile and it was heated to get clear solution. Water was added slowly to the reaction mass. The reaction mass was stirred and cooled. The separated solid was washed with water and then dried.
- the Naratriptan base was dissolved in methanol and it was heated to get a clear solution. Water was added slowly to the reaction mass. The reaction mass was stirred and cooled. The separated solid was washed with water and then dried.
- N-methyl-2-[3-(l-methyl-4-piperidyl)-lH-indol-5-yl]-ethane sulfonamide is dissolved in ethyl acetate and heated to get a clear solution.
- the solution was filtered through hyflow and the filterate was cooled to 25-30 0 C.
- Methanolic /HCl was added drop wise and the reaction mass was stirred for 2Hours.
- the solid was separated out and washed with ethyl acetate. The solid was dried at 80-85 0 C to get N-methyl-2-[3-(l-methyl-4- ⁇ iperidyl)-lH-indol-5-yl]-ethane sulfonamide.
- the Naratriptan base (10 g) was dissolved in methanol and heated to get clear solution.
- the reaction mass was cooled to room temperature and treated with carbon.
- the reaction mass was stirred and filtered through Hyflow. IPA/HC1 was added to the filtrate at room temperature and stirred.
- the separated solid was filtered, washed with methanol and dried to obtain 7g title product.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention provides a process for the preparation of Naratriptan hydrochloride which comprises decarboxylation of 5-{2-[(methylamino) sulfonyl] ethyl}-1H-indole-2-carboxylic acid to get 2-(1H-indol-5-yl)-N-methylethanesulfonamide using sulfolane as a solvent, and further reacting 2-(1H-indol-5-yl)-N-methylethanesulfonamide to obtain Naratriptan hydrochloride.
Description
A PROCESS FOR THE PREPARATION OF NARATRIPTAN HYDROCHLORTOE
The following specification describes the nature of the invention and the manner in which it has to be performed.
Field of the invention
The present invention relates to an improved process for the preparation of Naratriptan and its pharmaceutically acceptable salt, an antimigraine drug.
Background of the invention
Naratriptan hydrochloride is a selective 5-hydroxytryptamine-l receptor subtype agonist. It is chemically designated as N-methyl-3-(l-methyl-4-piperidinyl)- lH-indole-5-ethanesulfonamide monohydrochloride and represented by the following formula I
2-(lH-indol-5-yl)-N-methylethane sulfonamide of formula III is one of the key intermediates in the synthesis of Naratriptan hydrochloride, which is obtained by decarboxylation of 5-{2-[methylamino)sulfonyl]ethyl}-lH-indole-2-carboxylic acid of formula II.
N-methyl-3-(l-methyl-4-piperidinyl)-lH-indole-5-ethanesulfonamide and its physiologically acceptable salts are reported in British patent GB2208646 for the treatment of human suffering from migraine, cluster headache and chronic paroxysmal hemicrania. This patent describes a process for the preparation of Naratriptan hydrochloride by reducing the N-methyl-2-[3-(l,2,3,6-tetrohydro-l-methyl-4- pyridinyl)-lH-indol-5-yl]-ethenesulphonamide of formula IV
IV
The Journal of Organic Chemistry 1957 (22), 85 describes that 7-nitroindole is obtained by decarboxylation of 7-nitroindole-2-carboxylicacid using quinoline and trace of copper chromate.
Another article Synthetic Communications 22(14), 2103-2109, (1992) describes the decarboxylation of 6-methoxyindole 2-carboxylicacid by using copper powder and quinoline solution to obtain 6-methoxyindole.
Most of the prior art processes used quinoline as a solvent for decarboxylation, which is sparingly soluble in water and hence needs high temperature to dissolve. The present inventors surprisingly found that the decarboxylation of indole carboxylic acid using copper or copper salts and sulfolane overcomes the drawbacks associated with the prior art processes.
US patents 4,997,841 describes a process for preparation of N-methyl-3-(l- methyl-4-piperidinyl)~lH-indole-5-ethanesulfonamide which is obtained by condensation of l-methylpiperidine-4-one with 2-(lH-indol-5yl)-N- methylethanesulfonamide in presence of methanol and followed by reduction. The obtained compound is purified by flash chromatography.
In most of the prior art process, where the condensation is carried out only in an alcohol, the duration of the reaction is longer. Further the purification of the reduced product i.e. Naratriptan base is carried out by flash chromatography which is not feasible at industrial scale.
The present inventors found that using water along with alcohol for the condensation of l-methylpiperidine-4-one with 2-(lH-indol-5yl)-N- methylethanesulfonamide not only reduces the reaction time but it reduces the formation of impurity significantly. The inventors also surprisingly found that purification of the Naratriptan base by using an organic solvent or a mixture of it with water, gives a highly pure product.
The present invention has following advantages.
1. The process involves simple and cheap reagents like ethyl pyruvate, HBr in acetic acid, sulfolane etc.,
2. Decarboxylation of indole-2-carboxylic acid is carried out in sulfolane with Copper salts specially Copper oxide out at 185-2000C, which is highly soluble in water.
3. The workup after decarboxylation is simple as compared to the prior arts in which Quinoline with copper and its salt is used at temp, ranging from 200- 2400C. 4. Hydrogenation of N-methyl-2-[3-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)-lH- indol-5-yl]ethane sulfonamide is carried out in a mixture of methanol 10 volume and 0.5 volume of acetic acid with 5% wet Pd/C at 60 psi. Whereas, the prior are process uses a mixture of methanol in dimethyl formamide in higher volumes.
Object of the invention
The main objective of the present invention is to provide a novel process for the preparation of Naratriptan Hydrochloride.
Another objective of the present invention is to provide a process which results in better yield and purity.
Yet another objective of the process is to provide a process, which is more economical and commercially viable in industrial scale.
Summary of the invention
The present invention provides a process for the preparation of Naratriptan and its pharmaceutical acceptable salts comprising the steps of:
a) condensation of 2-(4-hydrazinophenyl)-N-methylethanesulfonamide of Formula V , with ethyl 2-oxopropanate of formula VI to get Ethyl (2Z)-2-[(4- {methylamino) sulfonyl]ethyl}phenyl) hydrazono] propanate of formula VII; b) cyclisation of compound of formula VII to obtain ethyl 5-{2-[(methylamino) sulfonyl] ethyl } - 1 H-indole-2-carboxylate of formula VIII; c) saponification of formula VIII to get 5-{2-[(methylamino) sulfonyl] ethyl}-lH- indole-2-carboxylic acid of formula II; d) decarboxylation of formula II in presence of sulfolane and copper salts to get 2- (lH-indol-5-yl)-N-methylethanesulfonamide of formula III; e) condensation of formula III with l-methylpiperidin-4-one using an organic solvent or its mixture with water to get N-methyl-2-[3-(l-methyl-l,2,3,6- tetrahydropyridin-4-yl)-lH-indol-5-yl]ethanesulfonamide of formula IX; f) hydrogenation of Formula IX to get Naratriptan free base of formula X; g) optionally purifying Naratriptan free base of formula X in aqueous organic solvent; and h) conversion of Naratriptan free base of formula X to its pharmaceutically acceptable salts.
The above process may be represented by the following reaction scheme:
Detailed description of the invention
In an embodiment of the present invention the condensation of 2-(4- hydrazinophenyl)-N-methylethanesulfonamide of Formula V with ethyl 2- oxopropanate of formula VI to get Ethyl (2Z)-2-[(4-{methylamino) sulfonyl]ethyl}phenyl) hydrazono] propanate of formula VII is carried out in an alcohol selected from the group consisting of methanol, ethanol, propanol and isopropanol, preferably methanol.
In another embodiment of the present invention the cyclisation is carried out using HBr in acetic acid.
In another embodiment of the present invention saponification is carried out in aqueous alkali solution, where alkali solution is selected from NaOH, KOH and the like,
In another embodiment of present invention, the decarboxylation of 5-{2- [(methylamino) sulfonyl] ethyl}-lH-indole-2-carboxylic acid is carried out using catalytic amount of copper or copper salts and sulfolane as a solvent.
In another embodiment of present invention, the condensation of 2-(lH-indol-5- yl)-N-methylethanesulfonamide with l-methylpiperidin-4-one is carried out in presence of alkali using Organic or aqueous organic solution, wherein, organic solvent is selected from -methanol, ethanol, n-propanol, isopropanol and the like, preferably methanol.
In yet another embodiment of present invention, the hydrogenation of N- methyl-2-[3-(l-methyl-l,2,3,6-tetrahydrόpyridin-4-yl)-lH-indol-5-yl]ethane sulfonamide is carried out in presence of Pd/C using organic solvent with acetic acid to get Naratriptan free base. Preferably the organic solvent is methanol.
In another embodiment of present invention, the conversion of Naratriptan free base to hydrochloride salt is carried out by dissolving Naratriptan free base in an organic solvent and converting to hydrochloride using alcoholic HCl. The organic solvent is selected from methanol, ethanol, n-propanol, isopropanol, esters such as ethyl acetate and the like and alcoholic HCl is MeOH/HCl, EtOH/HCl or IPA/HC1.
In yet another embodiment of the present invention wherein the reaction is performed at a temperature in the range of -10 0C to reflux temperature preferably 20 to 200 0C.
The invention is further illustrated by the following examples, which should not be construed to limit the scope of the invention in anyway.
Example 1
Ethyl (2Z)-2-[(4-{2-[(methyIamino) sulfonyl] ethyl} phenyl) hydrazono] propanoate
2-(4-hydrazinophenyl)-N-methylethanesulfonamide (1 mole) and ethyl 2- oxopropanoate (1.1 Mole) was taken in methanol at room temperature and stirred for 2 hours. The reaction mass was cooled to 10-150C filtered and washed with methanol to get solid.
Yield 60-80% Example 2 Ethyl 5-{2-[(methylamino) sulfonyl] ethyl}-lH-indo!e-2-carboxyIate
Ethyl (2Z)-2-[(4-{2-[(methylamino) sulfonyl] ethyl} phenyl) hydrazono] propanoate was taken in glacial aceticacid. 33% HBr in acetic acid was added drop wise at 20-300C and stirred for 2 hours then cooled. Water was added drop wise to separate the solid, filtered and washed with water.
Example 3
5-{2-[(methylamino) sulfonyl] ethyl}-lH-indole-2-carboxyIic acid
Ethyl 5-{2-[(methylamino) sulfonyl] ethyl} -IH-indole-2-carboxylate was taken in sodium hydroxide in water. The reaction mass was heated for 1 hours at 50-600C, stirred and cooled. The pH was adjusted to ~ 2-3 by using 1 : 1 hydrochloric acid. The solid was separated out, filtered and washed with water. The solid was dried at 60-700C
Yield -80%.
Example 4
2-(lH-indoI-5-yl)-N-methylethanesulfonamide
5-{2-[(methylamino) sulfonyl] ethyl} -lH-indole-2-carboxylic acid and copper oxide (0.1%w/W/W) was taken in sulfolane. The reaction mass was heated to 185-2000C for
2-3 hours. The reaction mass was cooled to room temperature and filtered. The filtrate
was added to water and stirred for 30 minutes and filtered. The solid was washed with water and purified with ethyl acetate and hexane.
Yield 60-80% M.P 115°C
Example 5
N-methyl-2-[3-(l-methyl-l,2,3,6-tetrahydropyridin-4-yl)-lH-indol-5-yl]ethane sulfonamide
2-(lH-indol-5yl)-N-methylethanesulfonamide and l-methylpiperidine-4-one was added to a mixture of (1:1) methanol and water and potassium hydroxide solution. The reaction mass was heated upto reflux temperature. After completion of the reaction, the reaction mass was cooled, stirred and filtered. The solid obtained was washed with water and dried.
Example 6
Preparation of N-methyl-2-[3-(l-methyI-l,2,3,6 tetrahydopyridin-4-yl)-lH-indol- 5yl]-ethanesulfonamide
2-(lH-indol-5yl)-methylethanesulfonamide and l-methylpiperidine-4-one was added to a solution of methanol and potassium hydroxide. The reaction mass was heated upto reflux temperature. After completion of the reaction, the reaction mass was cooled and of isopropanol was added to the reaction mass. The reaction mass was cooled and stirred for 30 minutes and then filtered. The solid obtained was washed with chilled isopropanol and dried.
Example 7
Preparation of Naratriptan base
N-methyl-2-[3-(l-methyl-l,2,3,6 tetrahydopyridin-4-yl)-lH-indol-5yl]-ethane sulfonamide (5 g) was dissolved in methanol and acetic acid in 1 lit autoclave. To this solution, 5% wet Pd/C was added. Hydrogen was flushed to the reaction mass at room temperature. The pressure was maintained at 10 kg. After completion of the reaction,
the reaction mass was filtered through Hyflow and concentrated. A solution of sodium carbonate and ethyl acetate was added to the reaction mass and stirred. The aqueous layer was extracted with ethylacetate and combined organic layer was charcolised with 10% carbon. The filtrate was distilled up and cooled to room temperature and stirred for another 30 minutes. The reaction mass was filtered and washed with ethylacetate. The solid obtained was dried to obtain 3.5 gm of the title product.
Example 8 Purification of Naratriptan base using acetonitrile: water
The Naratriptan base was dissolved in acetonitrile and it was heated to get clear solution. Water was added slowly to the reaction mass. The reaction mass was stirred and cooled. The separated solid was washed with water and then dried.
Example 9
Purification of Naratriptan base using methanol: water
The Naratriptan base was dissolved in methanol and it was heated to get a clear solution. Water was added slowly to the reaction mass. The reaction mass was stirred and cooled. The separated solid was washed with water and then dried.
Example 10
N-methyl-2-[3-(l-methyl-4-piperidyI)-lH-indol-5-yl]-ethane sulfonamide. Hydrochloride (Naratriptan hydrochloride)
N-methyl-2-[3-(l-methyl-4-piperidyl)-lH-indol-5-yl]-ethane sulfonamide is dissolved in ethyl acetate and heated to get a clear solution. The solution was filtered through hyflow and the filterate was cooled to 25-300C. Methanolic /HCl was added drop wise and the reaction mass was stirred for 2Hours. The solid was separated out and washed with ethyl acetate. The solid was dried at 80-850C to get N-methyl-2-[3-(l-methyl-4- ρiperidyl)-lH-indol-5-yl]-ethane sulfonamide. Hydrochloride
M.p 237-2400C.
Example 11
Preparation of Naratriptan Hydrochloride
The Naratriptan base (10 g) was dissolved in methanol and heated to get clear solution. The reaction mass was cooled to room temperature and treated with carbon. The reaction mass was stirred and filtered through Hyflow. IPA/HC1 was added to the filtrate at room temperature and stirred. The separated solid was filtered, washed with methanol and dried to obtain 7g title product.
Claims
1. A process for the preparation of Naratriptan of formula X and its pharmaceutical acceptable salts comprising the steps of:
a) condensation of 2-(4-hydrazinophenyl)-N-methylethanesulfonamide of Formula V with ethyl 2-oxopropanate of formula VI to get Ethyl (2Z)-2- [(4-{methylamino) sulfonyl]ethyl} phenyl) hydrazono] propanate of formula VII;
b) cyclisation of compound of formula VII to obtain ethyl 5-{2- [(methylamino) sulfonyl] ethyl}-lH-indole-2-carboxylate of formula VIII;
c) saponification of formula VIII to get 5-{2-[(methylamino) sulfonyl] ethyl}- lH-indole-2-carboxylic acid of formula II;
d) decarboxylation of formula II in presence of sulfolane and copper salts to get 2-(lH-indol-5-yl)-N-methylethanesulfonamide of formula III;
e) condensation of formula III with l-methylpiperidin-4-one using an organic solvent or its mixture with water to get N-methyl-2-[3-(l-methyl-l,2,3,6- tetrahydropyridin-4-yl)-lH-indol-5-yl]ethanesulfonamide of formula IX;
f) hydrogenation of Formula IX to get Naratriptan free base of formula X; g) optionally purifying Naratriptan free base of formula X in aqueous organic solvent; and h) conversion of Naratriptan free base of formula X to its pharmaceutically acceptable salts.
2. The process according to claim 1, wherein condensation of step (a) is carried out in an alcoholic solvent, preferably methanol.
3. The process according to claim 1, wherein cyclisation of step (b) is carried out in HBr and acetic acid.
4. The process according to claim 1, wherein saponification of step (c) is carried out in an aqueous alkali solution, preferably aqueous sodium hydroxide.
5. The process according to claim 1, wherein the organic solvent of step (e) is alcoholic solvent, preferably methanol.
6. A process for the purification of Naratriptan free base which comprises i. dissolving naratriptan in a first solvent; ii. adding second solvent to the reaction mass; and iii. isolating pure Naratriptan
7. The process according to claim 6, wherein the first solvent is selected from acetonitrile, methanol, ethanol, isopropanol and the second solvent is water.
8. A process according to claim 1, wherein Naratriptan free base is converted to its pharmaceutically acceptable salts by dissolving Naratriptan free bas in a lower aliphatic alcohol, ethyl acetate followed by treating with alcoholic solution of hydrogen chloride.
9. The process according to claim 8, wherein the lower aliphatic alcohol is selected from methanol, ethanol, isopropanol and butanol.
10. The process according to claim 8, wherein alcoholic solution of hydrogen chloride is IPA/HCl, ethanol/HCl or methanol/HCl.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1656/CHE/2007 | 2007-07-30 | ||
IN1656CH2007 | 2007-07-30 | ||
IN2992/CHE/2007 | 2007-12-14 | ||
IN2992CH2007 | 2007-12-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009016466A2 true WO2009016466A2 (en) | 2009-02-05 |
WO2009016466A3 WO2009016466A3 (en) | 2011-06-03 |
Family
ID=40304970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2008/001971 WO2009016466A2 (en) | 2007-07-30 | 2008-07-30 | A process for the preparation of naratriptan hydrochloride |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009016466A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009118753A2 (en) * | 2008-03-07 | 2009-10-01 | Usv Limited | Process for preparation of naratriptan hydrochloride |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997841A (en) * | 1987-08-13 | 1991-03-05 | Glaxo Group Limited | Indole derivatives |
WO2006010079A2 (en) * | 2004-07-08 | 2006-01-26 | Dr. Reddy's Laboratories Ltd. | Process for preparing naratriptan hydrochloride |
CN1789262A (en) * | 2004-12-16 | 2006-06-21 | 上海美通生物科技有限公司 | Improvement of preparation of Naratriptan |
-
2008
- 2008-07-30 WO PCT/IB2008/001971 patent/WO2009016466A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997841A (en) * | 1987-08-13 | 1991-03-05 | Glaxo Group Limited | Indole derivatives |
WO2006010079A2 (en) * | 2004-07-08 | 2006-01-26 | Dr. Reddy's Laboratories Ltd. | Process for preparing naratriptan hydrochloride |
CN1789262A (en) * | 2004-12-16 | 2006-06-21 | 上海美通生物科技有限公司 | Improvement of preparation of Naratriptan |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009118753A2 (en) * | 2008-03-07 | 2009-10-01 | Usv Limited | Process for preparation of naratriptan hydrochloride |
WO2009118753A3 (en) * | 2008-03-07 | 2010-01-28 | Usv Limited | Process for preparation of naratriptan hydrochloride |
Also Published As
Publication number | Publication date |
---|---|
WO2009016466A3 (en) | 2011-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014026657A2 (en) | A process for the preparation of a derivative of 2-methyl-2'-phenylpropionic acid using new intermediates | |
US20120253038A1 (en) | Processes for the synthesis of bazedoxifene acetate and intermediates thereof | |
AU2011281421A1 (en) | Process for preparing aminobenzoylbenzofuran derivatives | |
US10392364B2 (en) | Process for synthesis of lenalidomide | |
WO2011039782A1 (en) | Processes for preparing imatinib and pharmaceutically acceptable salts thereof | |
CZ302424B6 (en) | Process for preparing almotriptan of high purity | |
EP4313987A2 (en) | Process for the preparation of ribociclib and pharmaceutically acceptable salts thereof | |
WO2009016466A2 (en) | A process for the preparation of naratriptan hydrochloride | |
US9745264B2 (en) | Method for preparing silodosin and intermediate thereof | |
KR20100019674A (en) | Process for preparing highly pure rebamipide | |
JP2012524736A5 (en) | ||
EP1907377B1 (en) | A process for the preparation of almotriptan | |
US8754239B2 (en) | Process for preparing eletriptan hydrobromide having α-form | |
US20220324839A1 (en) | Process for preparing pyrimidinyl bipyridine compound and intermediate therefor | |
WO2008072257A2 (en) | Process for the preparation of indole derivatives | |
WO2013001511A1 (en) | Novel salt intermediates for the synthesis of bazedoxifene acetate and process thereof | |
WO2009084030A2 (en) | Improved process for the preparation of (1-benzyl-4-(5,6,- dimethoxyind anone-2-yl)methylpiperidine) hydrochloride-form iii | |
US7122674B2 (en) | Process for preparing high-purity hydroxyindolylglyoxylamides | |
WO2005040115A1 (en) | Process for the preparation of ropinirole | |
CN110862325B (en) | Preparation method of (1R,3S) -3-amino-1-cyclopentanol and salt thereof | |
WO2007010557A2 (en) | Process for the preparation of highly pure ropinirole | |
SK13592001A3 (en) | Synthesis of 3-amino-3-aryl propanoates | |
WO2008084499A1 (en) | An industrial process for the preparation of pure ropinirole | |
US20070037854A1 (en) | Process for preparing sulfonamide-containing indole compounds | |
JP2023522800A (en) | Process for the manufacture of Tofacitinib and its intermediates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08788949 Country of ref document: EP Kind code of ref document: A2 |